β-2 microglobulin in renal disease

Journal of the American Society of Nephrology

Volumn 9, Issue 9, 1998, Pages 1723-1735

  Miyata, Toshio ^a   Jadoul, Michel ^b   Kurokawa, Kiyoshi ^a   Van Ypersele De Strihou, Charles ^b  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF LOUVAIN MEDICAL SCHOOL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID P COMPONENT; BETA 2 MICROGLOBULIN; GLYCOSYLATED PROTEIN;

AMYLOIDOSIS; ARTHROPATHY; BONE RADIOGRAPHY; CARPAL TUNNEL SYNDROME; DIALYSIS MEMBRANE; HEMODIALYSIS; HUMAN; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN MODIFICATION; REVIEW; RISK FACTOR; UREMIA;

EID: 0031782771     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (143)

1. Berggard I, Bearn AG: Isolation and properties of a low molecular weight β2-globulin occurring in human biological fluid. J Biol Chem 213: 4095-4103, 1968
2. Cunningham BA, Berggard I: Structure, evolution and significance of β2-microglobulin. Transplant Rev 21: 3-14, 1974
3. Harris HW, Gill TJ III: Expression of class I transplantation antigens. Transplantation 42: 109-117, 1986
4. Bernier GM, Fanger MW: Synthesis of β2-microglobulin by stimulated lymphocytes. J Immunol 109: 407-409, 1973
5. Poulik MD, Blood AD: β2-microglobulin production and secretion by lymphocytes in culture. J Immunol 110: 1430-1433, 1973
6. Karlsson FA, Groth T, Sege K, Wibell L, Peterson PA: Turnover in humans of β2-microglobulin: The constant chain of HLA-antigens. Eur J Clin Invest 10: 293-300, 1980
7. Beorchia S, Vincent C, Revillard JP, Trepo C: Elevation of serum β2-microglobulin in liver diseases. Clin Chim Acta 109: 245-255, 1981
8. Revillard JP: La β2-microglobuline: Structure, fonction et métabolisme. Lyon Méd 241: 681-690, 1979
9. Schuster J, Gold P, Poulik MD: β2-microglobulin levels in cancerous and other disease states. Clin Chem Acta 67: 307-313, 1976
10. Bernier GM, Conrad ME: Catabolism of β2-microglobulin by the rat kidney. Am J Physiol 217: 1350-1362, 1969
11. Shea PH, Maher JF, Horak E: Prediction of glomerular filtration rate by serum creatinine and β2-microglobulin. Nephron 29: 30-35, 1981
12. Vincent C, Revillard JP: Serum levels and urinary excretion of β2m in patients under hemodialysis or after renal transplantation. Acta Clin Belg 25[Suppl 10]: 31-39, 1990
13. Eddy AA, McCulloch L, Liu E, Adams J: A relationship between proteinuria and acute tubulointerstitial disease in rats with experimental nephrotic syndrome. Am J Pathol 138: 1111-1123, 1991
14. Holm J, Hemmingsen L, Nielsen NV: Low-molecular-mass proteinuria as a marker of proximal renal tubular dysfunction in normo- and microalbuminuric non-insulin-dependent diabetic subjects. Clin Chem 39: 517-519, 1993
15. Kabanda A, Jadoul M, Lauwerys R, Bernard A, van Ypersele de Strihou C: Low molecular weight proteinuria in Chinese herbs nephropathy. Kidney Int 48: 1571-1576, 1995
16. Kabanda A, Vandercam B, Bernard A, Lauwerys R, van Ypersele de Strihou C: Low molecular weight proteinuria in human immunodeficiency virus-infected patients. Am J Kidney Dis 27: 803-808, 1996
17. Assenat H, Calemard E, Charra B, Laurent G, Terrat JC, Vanel T: Hémodialyse: Syndrome du canal carpien et substance amyloïde. Nouv Presse Méd 24: 1715, 1980
18. Gejyo F, Yamada T, Odani S, Nakagawa Y, Arakawa M, Kunitomo T, Kataoka H, Suzuki M, Hirasawa Y, Shirahama T: A new form of amyloid protein associated with chronic hemodialysis was identified as β2-microglobulin. Biochem Biophys Res Commun 129: 701-706, 1985
19. Gorevic PD, Munoz PC, Casey TT, DiRaimondo CR, Stone WJ, Prelli FC, Rodrigues MM, Pouli MD, Frangione B: Polymerization of intact β2-microglobulin in tissue causes amyloidosis in patients on chronic hemodialysis. Proc Natl Acad Sci USA 83: 7908-7912, 1986
20. Athanasou NA: Description, localization, and progression of β2-microglobulin dialysis-related amyloid deposition. In: Dialysis Amyloid, edited by van Ypersele C, Drüeke TB, Oxford University Press, 1996, pp 173-191
21. Bardin T: Arthropathy and carpal tunnel syndrome of β2-microglobulin amyloidosis. In: Dialysis Amyloid, edited by van Ypersele C, Drüeke TB, Oxford University Press, 1996, pp 71-97
22. Charra B, Calemard E, Laurent G: Chronic renal failure treatment duration and mode: Their relevance to the late dialysis periarticular syndrome. Blood Purif 6: 117-124, 1988
23. van Ypersele de Strihou C, Honhon B, Vandenbroucke JM, Huaux JP, Noel H, Maldague B: Dialysis amyloidosis. In: Advances in Nephrology, edited by Grünfeld JP, Bach JF, Funck-Brentano JL, Year Book Medical Publishers, Inc., Vol. 117, 1988, pp 401-422
24. Borgatti PP, Lusenti T, Franco V, Anelli A, Brancaccio D: Guyon's syndrome in a long-term haemodialysis patient. Nephrol Dial Transplant 6: 734-735, 1991
25. Jadoul M, Garbar C, Noël H, Sennesael J, Vanholder R, Bernaert P, Rorive G, Hanique G, van Ypersele de Strihou C: Histological prevalence of β2-microglobulin amyloidosis in hemodialysis: A prospective post-mortem study. Kidney Int 51: 1928-1932, 1997
26. Argilés A, Mourad G, Kerr PG, García M, Collins B, Demaille JG: Cells surrounding haemodialysis-associated amyloid deposits are mainly macrophages. Nephrol Dial Transplant 9: 662-667, 1994
27. Brown EA, Arnold IR, Gower PE: Dialysis arthropathy: Complication of long term treatment with haemodialysis. Br Med J 292: 163-166, 1986
28. Cary NRB, Sethi D, Brown EA, Erhardt CC, Woodrow DF, Gower PE: Dialysis arthropathy: Amyloid or iron? Br Med J 293: 1392-1394, 1986
29. Muñoz-Gómez J, Gómez-Pérez R, Solé-Arques M, Llopart-Buisán E: Synovial fluid examination for the diagnosis of synovial amyloidosis in patients with chronic renal failure undergoing haemodialysis. Ann Rheum Dis 46: 324-326, 1987
30. Brancaccio D, Gallieni M, Padovese P, Anelli A, Coggi G, Uslenghi C: Dialysis amyloidosis with massive popliteal deposition of β2-microglobulin amyloid [Letter]. Lancet 2: 802, 1988
31. Fernández E, Baró P, Montoliu J, Campistol JM, Solé M: Dialysis-associated amyloidosis presenting as a tumour in the elbow. Nephrol Dial Transplant 5: 237-238, 1990
32. Kuntz D, Naveau B, Bardin T, Drüeke T, Treves R, Dryll A: Destructive spondyloarthropathy in hemodialysed patients: A new syndrome. Arthritis Rheum 27: 369-375, 1984
33. Bindi P, Chanard J: Destructive spondyloarthropathy in dialysis patients: An overview. Nephron 55: 104-109, 1990
34. Allain TJ, Stevens PE, Bridges LR, Phillips ME: Dialysis myelopathy: Quadriparesis due to extradural amyloid of β2 microglobulin origin. Br Med J 296: 752-753, 1988
35. Kröner G, Stäbler A, Seiderer M, Moran JE, Gurland HJ: β2 microglobulin-related amyloidosis causing atlantoaxial spondylarthropathy with spinal-cord compression in haemodialysis patients: Detection by MRI. Nephrol Dial Transplant 2: 91-95, 1991
36. Koch KM: Dialysis-related amyloidosis. Kidney Int 41: 1416-1429, 1992
37. Huaux JP, Noël H, Malghem J, Maldague B, Devogelaer JP, Nagant de Deuxchaisnes C: Erosive azotemic osteoarthropathy: Possible role of amyloidosis. Arthritis Rheum 28: 1075-1076, 1985
38. Campistol JM, Solé M, Muñoz-Gómez J, Riba J, Ramón R, Revert L: Pathological fractures in patients who have amyloidosis associated with dialysis. J Bone Joint Surg 72: 568-574, 1990
39. Gal R, Korzets A, Schwartz A, Rath-Wolfson L, Gafter U: Systemic distribution of β2-microglobulin-derived amyloidosis in patients who undergo long-term hemodialysis. Arch Pathol Lab Med 118: 718-721, 1994
40. Maher ER, Hamilton Dutoit S, Baillod RA, Sweny P, Moorhead JF: Gastrointestinal complications of dialysis related amyloidosis. Br Med J 297: 265-266, 1988
41. Choi H-SH, Heller D, Picken MM, Sidhu GS, Kahn T: Infarction of intestine with massive amyloid deposition in two patients on long-term hemodialysis. Gastroenterology 96: 230-234, 1989
42. Sethi D, Cary NRB, Brown EA, Woodrow DF, Gower PE: Dialysis-associated amyloid: Systemic or local? Nephrol Dial Transplant 4: 1054-1059, 1989
43. Shinoda T, Komatsu M, Aizawa T, Shirota T, Yamada T, Ehara T. Mizukami E: Intestinal pseudo-obstruction due to dialysis amyloidosis. Clin Nephrol 32: 284-289, 1989
44. Zhou H, Pfeifer U, Linke R: Generalized amyloidosis from β2-microglobulin, with caecal perforation after long-term haemodialysis. Virchows Arch Pathol Anat Physiol Klin Med 419: 349-353, 1991
45. Ikegaya N, Kobayashi S, Hishida A, Kaneko E, Furuhashi M, Maruyama Y: Colonic dilatation due to dialysis-related amyloidosis. Am J Kidney Dis 25: 807-809, 1995
46. Lutz AE, Schneider U, Ehlerding G, Frenzel H, Koch KM, Kühn K: Right ventricular cardiac failure and pulmonary hypertension in a long-term dialysis patient: unusual presentation of visceral β2-microglobulin amyloidosis. Nephrol Dial Transplant 3: 269-271, 1995
47. Araki H, Muramoto H, Oda K, Koni I, Mabuchi H, Mizukami Y: Severe gastrointestinal complications of dialysis-related amyloidosis in two patients on long-term hemodialysis. Am J Nephrol 16: 149-153, 1996
48. Matsuo K, Nakamoto M, Yasunaga C, Goya T, Sugimachi K: Dialysis-related amyloidosis of the tongue in long-term hemodialysis patients. Kidney Int 52: 832-838, 1997
49. Jadoul M, van Ypersele de Strihou C: β2-microglobulin amyloidosis. In: Complications of Long Term Dialysis, edited by Brown EA, Parfrey PS, Oxford University Press, in press
50. Cross PA, Bartley CJ, McClure J: Amyloid in prostatic corpora amylacea. J Clin Pathol 45: 894-897, 1992
51. Hardouin P, Flipo RM, Lecomte-Houcke M, Foissac-Gegoux P, Delcambre B: Amylose des hémodialysés: Recherche d'une diffusion générale par biopsie rectale. Presse Méd 16: 445-446, 1987
52. Varga J, Idelson BA, Felson D, Skinner M, Cohen AS: Lack of amyloid in abdominal fat aspirates from patients undergoing long-term hemodialysis. Arch Int Med 147: 1455-1457, 1987
53. Ohashi K, Hara M, Kawai R, Ogura Y, Honda K, Nihei H, Mimura N: Cervical discs are most susceptible to beta2-microglobulin amyloid deposition in the vertebral column. Kidney Int 41: 1646-1652, 1992
54. Maldague B, Malghem J, Van de Berg B: Radiology of dialysis amyloidosis. In: Dialysis Amyloid, edited by van Ypersele C, Drüeke TB, Oxford University Press, 1996, pp 98-135
55. van Ypersele de Strihou C, Jadoul M, Malghem J, Maldague B, Jamart J, the Working Party on Dialysis Amyloidosis: Effect of dialysis membrane and patient's age on signs of dialysis related amyloidosis. Kidney Int 39: 1012-1019, 1991
56. Kay J, Benson CB, Lester S, Corson JM, Pinkus GS, Lazarus JM, Owen WF Jr: Utility of high-resolution ultrasound for the diagnosis of dialysis-related amyloidosis. Arthritis Rheum 35: 926-932, 1992
57. Jadoul M, Malghem J, Van de Berg B, van Ypersele de Strihou C: Ultrasonographic detection of thickened joint capsules and tendons as marker of dialysis-related amyloidosis: A cross-sectional and longitudinal study. Nephrol Dial Transplant 8: 1104-1109, 1993
58. Cardinal E, Buckwalter KA, Braunstein EM, Raymond-Tremblay D, Benson MD: Amyloidosis of the shoulder in patients on chronic hemodialysis: Sonographic findings. Am J Roentgenol 166: 153-156, 1995
59. Jadoul M, Van de Berg B, Malghem J: Ultrasonography of the joints. In: Dialysis Amyloid, edited by van Ypersele C, Drüeke TB, Oxford University Press, 1996, pp 136-144
60. 123I-labeled serum amyloid P component. N Engl J Med 323: 508-513, 1990
61. 123I-Serum amyloid P component. Lancet 338: 335-338, 1991
62. Hachulla E, Maulin L, Deveaux M, Facon T, Blétry O, Vanhille P, Wechsler B, Godeau P, Levesque H, Hatron PY, Huglo D, Devulder B, Marchandise X: Prospective and serial study of primary amyloidosis with serum amyloid P component scintigraphy: From diagnosis to prognosis. Am J Med 101: 77-87, 1996
63. Jadoul M, Drüeke T, Zingraff J, van Ypersele de Strihou C: Does dialysis-related amyloidosis regress after transplantation? Nephrol Dial Transplant 12: 655-657, 1997
64. 131I-β2-microglobulin. Kidney Int 38: 1169-1176, 1990
65. Schaeffer J, Floege J, Koch KM: Whole-body scintigraphy. In: Dialysis Amyloid, edited by van Ypersele C, Drüeke TB, Oxford University Press, 1996, pp 145-155
66. Jadoul M, Noël H, van Ypersele de Strihou C: β2-Microglobulin amyloidosis in a patient treated exclusively by CAPD. Am J Kidney Dis 15: 86-88, 1990
67. Renaud H, Fournier A, Morinière PH: Erosive osteoarthropathy associated with β2-microglobulin amyloidosis in a uraemic patient treated exclusively by long-term haemofiltration with biocompatible membranes. Nephrol Dial Transplant 3: 820-822, 1988
68. Jadoul M, Garbar C, Vanholder R, Sennesael J, Michel C, Noel H, van Ypersele de Strihou C: Prevalence of histological β2 microglobulin amyloidosis in CAPD patients compared with HD patients. Kidney Int 1998, in press
69. Zingraff JJ, Noel LH, Bardin T, Atienza C, Zins B, Drüeke TB, Kuntz D: β2-Microglobulin amyloidosis in chronic renal failure. N Engl J Med 323: 1070-1071, 1990
70. Vandenbroucke JM, Jadoul M, Maldague B, Huaux JP, Noël H, van Ypersele de Strihou C: Possible role of dialysis membrane characteristics in amyloid osteoarthropathy. Lancet 1: 1210-1211, 1986
71. Chanard J, Bindi P, Lauvaud S, Toupance O, Maheut H, Lacour F: Carpal tunnel syndrome and type of dialysis membrane. Br Med J 298: 867-868, 1989
72. Küchle D, Fricke H, Held E, Schiffl H: High-flux hemodialysis postpones clinical manifestation of dialysis-related amyloidosis. Am J Nephrol 16: 484-488, 1996
73. van Ypersele de Strihou C, Jadoul M: Prevention and treatment of β2-microglobulin amyloidosis. In: Dialysis Amyloid, edited by van Ypersele C, Drüeke TB, Oxford University Press, 1996, pp 261-276
74. Kabanda A, Jadoul M, Pochet JM, Lauwerys R, van Ypersele de Strihou C, Bernard A: Determinants of the serum concentrations of low molecular weight proteins in patients on maintenance hemodialysis. Kidney Int 45: 1689-1696, 1994
75. McCarthy JT, Williams AW, Johnson WJ: Serum β2-microglobulin concentration in dialysis patients: Importance of intrinsic renal function. J Lab Clin Med 123: 495-505, 1994
76. Sonikian M, Gogusev J, Zingraff J, Loric S, Quednau B, Bessou G, Siffert W, Drüeke TB, Keusch HP, Luft FC: Potential effect of metabolic acidosis on β2-microglobulin generation: In vivo and in vitro studies. J Am Soc Nephrol 7: 350-356, 1996
77. Mrowka C, Schiffl H: Comparative evaluation of β2-microglobulin removal by different hemodialysis membranes: A sixyear follow-up. Nephron 63: 368-369, 1993
78. Zingraff J, Drüeke TB, Chanard J: Factors modifying removal and production of β2-microglobulin. In: Dialysis Amyloid, edited by van Ypersele C, Drüeke TB, Oxford University Press, 1996, pp 225-245
79. Kabanda A, Goffin E, Bernard A, Lauwerys R, van Ypersele de Strihou C: Factors influencing serum levels and peritoneal clearances of low molecular weight proteins in continuous ambulatory peritoneal dialysis. Kidney Int 48: 1946-1952, 1995
80. van Ypersele de Strihou C, Floege J, Jadoul M, Koch KM: Amyloidosis and its relationship to different dialysers. Nephrol Dial Transplant 9[Suppl 2]: 156-161, 1994
81. Zaoui PM, Stone WJ, Hakim RM: Effects of dialysis membranes on beta2-microglobulin production and cellular expression. Kidney Int 38: 962-968, 1990
82. Canaud B, Assounga A, Kerr, Aznar R, Mion C: Failure of a daily haemofiltration programme using a highly permeable membrane to return β2-microglobulin concentrations to normal in haemodialysis patients. Nephrol Dial Transplant 7: 924-930, 1992
83. Connors LH, Shirahama T, Skinner M, Fenves A, Cohen AS: In vitro formation of amyloid fibrils form intact β2-microglobulin. Biochem Biophys Res Commun 131: 1063-1068, 1985
84. Stoppini M, Bellotti V, Mangione P, Merlini G, Ferri G: Use of anti-(β2 microglobulin) mAb to study formation of amyloid fibrils. Eur J Biochem 249: 21-26, 1997
85. Linke RP, Hampl H, Lobeck H, Ritz E, Bommer J, Waldherr R, Eulitz M: Lysine-specific cleavage of β2-microglobulin in amyloid deposits associated with hemodialysis. Kidney Int 36: 675-681, 1989
86. Campistol JM: Determinants of fibril precipitation and aggregation in amyloid deposits. In: Dialysis Amyloid, edited by van Ypersele C, Drüeke TB, Oxford Clinical Nephrology Series, Oxford University Press, 1996, pp 246-258, 1996
87. Argilés A, Derancourt J, Jauregul-Adell J, Mion C, Demaille JG: Biochemical characterization of serum and urinary beta 2 microglobulin in end-stage renal disease patients. Nephrol Dial Transplant 7: 1106-1110, 1992
88. Ogawa H, Saito A, Oda O, Nakajima M, Chung TG: Detection of novel β2-microglobulin in the serum of hemodialysis patients and its amyloidogenic predisposition. Clin Nephrol 30: 158-163, 1988
89. Odani H, Oyama R, Titani K, Ogawa H, Saito A: Purification and complete amino acid sequence of novel β2-microglobulin. Biochem Biophys Res Commun 168: 1223-1229, 1990
90. Miyata T, Oda O, Inagi R, Iida Y, Araki N, Yamada N, Horiuchi S, Taniguchi N, Maeda K, Kinoshita T: β2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. J Clin Invest 92: 1243-1252, 1993
91. Miyata T, Inagi R, Wada Y, Ueda Y, Iida Y, Takahashi M, Taniguchi N, Maeda K: Glycation of human β2-microglobulin in patients with hemodialysis-associated amyloidosis: Identification of the glycated sites. Biochemistry 33: 12215-12221, 1994
92. Brownlee M, Cerami A, Vlassara H: Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318: 1315-1321, 1988
93. Dyer DG, Dunn JA, Thorpe SR, Bailie KE, Lyons TJ, McCance DR, Baynes JW: Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 91: 2463-2469, 1993
94. Araki N, Ueno N, Chakrabarti B, Morino Y, Horiuchi S: Immunochemical evidence for the presence of advanced glycation end products in human lens proteins and positive correlation with aging. J Biol Chem 267: 10211-10214, 1992
95. Neeper M, Schmidt AM, Brett J, Van SD, Wang F, Pan YC, Elliston K, Stem D, Shaw A: Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267: 14998-15004, 1992
96. Schmidt AM, Yon SD, Brett J, Mora R, Nowygrod R, Stem D: Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J Clin Invest 92: 2155-2168, 1993
97. Miyata T, Hori O, Zhang JH, Yan SD, Ferran L, Iida Y, Schmidt AM: The receptor for advanced glycation end products mediates the interaction of AGE-β2-microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway: Implication for the pathogenesis of dialysis-related amyloidosis. J Clin Invest 98: 1088-1094, 1996
98. Sell DR, Lapolla A, Odetti P, Forgarty J, Monnier VM: Pentosidine formation in skin correlates with severity of complication in individuals with long standing IDDM. Diabetes 41: 1286-1292, 1992
99. McCance DR, Dyer DG, Dunn JA, Bailie KE, Thorpe SR, Baynes JW, Lyons TJ: Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Invest 91: 2470-2478, 1993
100. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, Friedman EA: Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 325: 836-842, 1991
101. Miyata T, Ueda Y, Shinzato T, Iida Y, Tanaka S, Kurokawa K, van Ypersele de Strihou C, Maeda K: Accumulation of albuminlinked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: Renal implications in the pathophysiology of pentosidine. J Am Soc Nephrol 7: 1198-1206, 1996
102. Miyata T, Ueda Y, Yoshida A, Sugiyama S, Iida Y, Jadoul M, Maeda K, Kurokawa K, van Ypersele de Strihou C: Clearance of pentosidine, an advanced glycation end product, by different modalities of renal replacement therapy. Kidney Int 51: 880-887, 1997
103. Sell DR, Monnier VM: Structure elucidation of a senescence cross-link from human extracellular matrix. J Biol Chem 264: 21597-21602, 1989
104. ε-carboxymethyllysine as a degradation product of fructoselysine in glycated protein. J Biol Chem 261: 4889-4894, 1986
105. Uchida K, Khor OT, Oya T, Osawa T, Yasuda Y, Miyata T: Protein modification by a Maillard reaction intermediate methylglyoxal: Immunochemical detection of fluorescent 5-methylimidazolone derivatives in vivo. FEBS Lett 410: 313-318, 1997
106. ε-(carboxymethyl)lysine is increased in uremia. Kidney Int 52: 1064-1067, 1997
107. Niwa T, Katzsuzaki T, Miyazaki S, Momoi T, Akiba, Miyazaki T. Nokura K, Hayase F, Tatemichi N, Takei Y: Amyloid β2-microglobulin is modified with imidazolone, a novel advanced glycation end product, in dialysis-related amyloidosis. Kidney Int 51: 187-194, 1997
108. Miyata T, Taneda S, Kawai R, Ueda Y, Horiuchi S, Hara M, Maeda K, Monnier VM: Identification of pentosidine as a native structure for advanced glycation end products in β2-microglobulin-containing amyloid fibrils in patients with dialysis-related amyloidosis. Proc Natl Acad Sci USA 93: 2353-2358, 1996
109. Miyata T, Wada Y, Cai Z, Eda Y, Horie K, Yasuda Y, Maeda K, Kurokawa K, van Ypersele de Strihou C: Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Kidney Int 51: 1170-1181, 1997
110. ε-(carboxymethyl)lysine in dialysis-related amyloidosis. Kidney Int 50: 1303-1309, 1996
111. Miyata T, Maeda K, Kurokawa K, van Ypersele de Strihou C: Oxidation conspires with glycation to generate noxious advanced glycation end products in renal failure. Nephrol Dial Transplant 12: 255-258, 1997
112. Baynes JW: Perspectives in diabetes: Role of oxidative stress in development of complications in diabetes. Diabetes 40: 405-412, 1991
113. Wells-Knecht KJ, Zyzak DV, Litchfield JE, Thorpe SR, Baynes JW: Mechanism of autoxidative glycosylation: Identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose. Biochemistry 34: 3702-3709, 1995
114. ε-(carboxymethyl)lysine, is a product of lipid peroxidation and glycoxidation reactions. J Biol Chem 271: 9982-9986, 1996
115. Dyer DG, Blackledge JA, Thorpe SR, Baynes JW: Formation of pentosidine during nonenzymatic browning of protein by glucose: Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J Biol Chem 266: 11654-11660, 1991
116. Loughrey CM, Young IS, Kightbody JH, McMaster D, McNamee PT, Trimble ER: Oxidative stress in haemodialysis. Q J Med 87: 679-683, 1994
117. Peuchant E, Carbonneau MA, Dubourg L, Thomas MI, Perromat A, Vallot C, Clerc M: Lipoperoxidation in plasma and red blood cells of patients undergoing haemodialysis: Vitamins A, E, and iron status. Free Radical Biol Med 16: 339-346, 1994
118. Canestrari F, Galli F, Giorgini A, Albertini MC, Galiotta P, Pascucci M, Bossu M: Erythrocyte redox state in uremic anemia: Effects of hemodialysis and relevance of glutathione metabolism. Acta Haematol 91: 187-193, 1994
119. Yeung JH: Effects of glycerol-induced acute renal failure on tissue glutathione and glutathione-dependent enzymes in the rat. Methods Find Exp Clin Pharmacol 13: 23-28, 1991
120. Kumano K, Yokota S, Go M, Suyama K, Sakai T, Era S, Sogami M: Quantitative and qualitative changes of serum albumin in CAPD patients. Adv Perit Dial 8: 127-130, 1992
121. Witko-Sarsat V, Friedlander M, Capelleire-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, Jungers P, Descamps-Latscha B: Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 49: 1304-1313, 1996
122. Friedlander MA, Witko-Sarsat V, Nguyen AT, Wu CY, Labrunie M, Verger C, Jungers P, Descamps-Latscha B: The advanced glycation end product pentosidine and monocyte activation in uremia, Clin Nephrol 45: 379-382, 1996
123. Miyata T, Inagi R, Iida Y, Sato M, Yamada N, Osa O, Maeda K, Seo H: Involvement of β2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis: Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-α and interleukin 1. J Clin Invest 93: 521-528, 1994
124. Iida Y, Miyata T, Inagi R, Sugiyama S, Maeda K: β2-Microglobulin modified with advanced glycation end products induces interleukin-6 from human macrophages: Role in the pathogenesis of hemodialysis-associated amyloidosis. Biochem Biophys Res Commun 201: 1235-1241, 1994
125. Miyata T, Iida Y, Ueda Y, Shinzato T, Seo H, Monnier VM, Maeda K: Monocyte/macrophage response to β2-microglobulin modified with the advanced glycation end products. Kidney Int 49: 538-550, 1996
126. Miyata T, Sprague SM: Advanced glycation of β2-microglobulin in the pathogenesis of bone lesions in dialysis associated amyloidosis. Nephrol Dial Transplant 11[Suppl 3]: 86-90, 1996
127. Miyata T, Notoya K, Yoshida K, Horic K, Kurokawa K, Maeda K, Taketomi S: Advanced glycation end products enhance osteoclast-induced bone resorption in cultured mouse unfractionated bone cells and in rats implanted subcutaneously with devitalized bone particles. J Am Soc Nephrol 8: 260-270, 1997
128. Athanasou NA, Puddle B, Sallie B: Highly sulfated glycosaminoglycans in articular cartilage and other tissues containing β2-microglobulin dialysis amyloid deposits. Nephrol Dial Transplant 10: 1672-1678, 1995
129. Hou FF, Chertow G, Kay J, Boyce J, Lazarus M, Braatz JA, Owen WF Jr: Interaction between β2-microglobulin and advanced glycation end products in the development of dialysis-related amyloidosis. Kidney Int 51: 1514-1519, 1997
130. Skroeder NR, Jacobson SH, Homquist B, Kjellstrand P, Kjellstrand CM: β2-Microglobulin generation and removal in long slow and short fast hemodialysis. Am J Kidney Dis 21: 519-526, 1993
131. Okutsu I, Hamanaka I, Ninomiya S, Takatori Y, Shimizu K, Ugawa Y: Results of endoscopic management of carpal-tunnel syndrome in long-term haemodialysis versus idiopathic patients. Nephrol Dial Transplant 8: 1110-1114, 1993
132. Goutallier D, Piat Ch, Kuntz D, Cazeau C, Juquel P, Moynot A, Zingraff J, Voisin MC, Bardin T: Surgical treatment of destructive spondylarthropathy in haemodialysis patients: A review of ten interbody fusion procedures in eight hemodialysis patients. Rev Rhum Mal Osteo-Artic 61[Suppl 9]: 101S-104S, 1994
133. Okutsu I, Ninomiya S, Takatori Y, Hamanaka I, Takemura T, Otsubo K, Otsubo O: Endoscopic management of shoulder pain in long-term haemodialysis patients. Nephrol Dial Transplant 6: 117-119, 1991
134. Takenaka R, Fukatsu A, Matsuo S, Ishikawa K, Toriyama T, Kawahara H: Surgical treatment of hemodialysis-related shoulder arthropathy. Clin Nephrol 38: 224-230, 1992
135. Laurent G, Charra B, Calemard E, Uzan M, Vanel T, Terrat JC: Amélioration par la dialyse péritonéale continue ambulatoire des douleurs abarticulaires accompagnant le syndrome du canal carpien des hémodialysés. Presse Méd 14: 2105-2106, 1985
136. Hardouin P, Flipo RM, Foissac-Gegoux P, Dumont A, Duquesnoy B, Delcambre B: Dialysis-related β2-microglobulin-amyloid arthropathy: Improvement of clinical symptoms after a switch of dialysis membranes. Clin Rheumatol 7: 41-45, 1988
137. Nakazawa R, Azuma N, Suzuki M, Nakatani M, Nankou T, Furuyoshi S: A new treatment for dialysis-related amyloidosis with β2-microglobulin adsorbent column. Int J Artif Organs 16: 823-829, 1993
138. Jadoul M, Malghem J, Pirson Y, Maldague B, van Ypersele de Strihou C: Effect of renal transplantation on the radiological signs of dialysis amyloid osteoarthropathy. Clin Nephrol 32: 194-197, 1989
139. Mourad G, Argilés A: Renal transplantation relieves the symptoms but does not reverse β2-microglobulin amyloidosis. J Am Soc Nephrol 7: 798-804, 1996
140. Tan SY, Irish A, Winearls CG, Brown EA, Gower PE, Clutterbuck EJ, Madhoo S, Lavender JP, Pepys MB, Hawkins PN: Long term effect of renal transplantation on dialysis-related amyloid deposits and symptomatology. Kidney Int 50: 282-289, 1996
141. Bardin T, Lebail-Darné JL, Zingraff J, Laredo JD, Voisin MC, Kreis H, Kuntz D: Dialysis arthropathy: Outcome after renal transplantation. Am J Med 99: 243-248, 1995
142. Jadoul M, Malghem J, Van de Berg B, van Ypersele de Strihou C: Ultrasonography of joint capsules and tendons in dialysis-related amyloidosis. Kidney Int 43[Suppl 41]: S106-S110, 1993
143. Jadoul M, Noel H, Malghem J, Galant C, van Ypersele de Strihou C: Histological beta-2-microglobulin amyloidosis 10 years after a successful renal transplantation. Am J Kidney Dis 27: 888-890, 1996